Stock fact sheet · data as of
KALA BIO, Inc. (KALA): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Speculative / Distressed
Is KALA undervalued?
KALA has a margin of safety of 100%: the stock closed at 0.1922 on 16 Oct 2026 against a GLS average fair value of 40.66. 1 of the 1 valuation models that produced a number sit above the price. Our screens treat a discount this large as a strong starting point for a cash-secured put, not as a verdict - the fair value is a model output, and a wide gap can mean the models are missing something the market knows.
The average is built from just 1 models (DCF) - the rest returned nothing because an input they need (dividends, free cash flow, book value) is zero or negative - so treat it with more caution than usual.
The nightly engine files KALA under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for KALA
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 40.66 | +21053% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | 0.3617 | +88% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 18.25 | +9395% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
KALA BIO, Inc. scores only 3 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 1.8/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -385.6%, ROE -385.6%, ROA -284.3% - with debt at 0.00 times equity and negative free cash flow.
KALA BIO, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Sales discounts and contractual fee for… 100% (quarter Q3 FY2022).
Institutional ownership scores 3/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 3 / 9 | ROIC | -385.6% |
|---|---|---|---|
| GLS Moat | 1.8 / 10 | ROE | -385.6% |
| Debt / equity | 0.00 | ROA | -284.3% |
| Free-cash-flow yield | -534.4% | Payout ratio | 0% |
| Institutions | 3 / 10 | Insiders · Congress | 1 · 5 / 10 |
Wheel Score 39: No options
No options are listed on KALA BIO, Inc. in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 39) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.
Volume runs at 858k shares a day on a market cap of $4M, with a beta of -2.41 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 12 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 100% margin of safety | |
| Health | 7 / 20 | Piotroski 3/9 | |
| Moat | 3 / 15 | moat 1.8/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 12 / 20 | 858k shares/day, $4M cap, beta -2.41 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 10 Nov 2026 (before the open), 25 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to KALA BIO, Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| APVO Aptevo Therapeutics Inc. | 1.70 | 5,120.14 | +100% | 33No options | $4M |
| ADXN Addex Therapeutics Ltd | 3.02 | 1.39 | -118% | 11No options | $4M |
| PMCB PharmaCyte Biotech, Inc. | 0.3485 | 2.22 | +84% | 38Weak | $4M |
| LNAI Lunai Bioworks Inc. | 0.8255 | 108.83 | +99% | 38Weak | $4M |
| ENLV Enlivex Therapeutics Ltd. | 0.2242 | 6,833.34 | +100% | 45Weak | $4M |
| DRMA Dermata Therapeutics, Inc. | 0.9100 | 7.66 | +88% | 39No options | $4M |
| ERNA Ernexa Therapeutics Inc. | 2.17 | 1.87 | -16% | 14No options | $4M |
| CVKD Cadrenal Therapeutics, Inc. Common Stock | 0.9700 | 1.73 | +44% | 36No options | $3M |
| EVGN Evogene Ltd. | 0.3999 | - | - | 24No options | $3M |
| CALC CalciMedica, Inc. | 1.08 | 0.0003 | -422318% | 13No options | $3M |
| JUNS Jupiter Neurosciences, Inc. | 3.14 | - | - | 26No options | $4M |
| CMND Clearmind Medicine Inc. | 6.42 | 7.99 | +20% | 31No options | $3M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about KALA
Is KALA undervalued right now?
By the GLS models, yes: at 0.1922 the stock is 100% below the average fair value of 40.66 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of KALA and what does it mean?
KALA has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for KALA?
40.66 per share as of 16 Oct 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does KALA BIO, Inc. report earnings next?
The next earnings report is due on 10 Nov 2026 (before the open), 25 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does KALA have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on KALA, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.